Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
$30.16
-4.9%
$31.24
$16.10
$35.83
$1.48B1.29490,499 shs759,264 shs
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
$158.43
+3.3%
$146.72
$60.00
$200.00
$6.15B-1.23173,803 shs136,538 shs
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
$40.50
$40.16
$12.74
$40.56
$6.27B1.112.15 million shsN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$86.54
-4.1%
$82.31
$23.30
$105.47
$5.62B2.111.33 million shs1.35 million shs
10 Best Stocks to Own - Summer 2026 Cover

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
-4.95%+6.87%-11.29%+0.40%+42.40%
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
+3.31%+3.66%+6.52%-0.19%+154.55%
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
0.00%0.00%0.00%+2.64%+162.82%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-4.13%-1.04%-13.32%+46.31%+140.46%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
$30.16
-4.9%
$31.24
$16.10
$35.83
$1.48B1.29490,499 shs759,264 shs
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
$158.43
+3.3%
$146.72
$60.00
$200.00
$6.15B-1.23173,803 shs136,538 shs
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
$40.50
$40.16
$12.74
$40.56
$6.27B1.112.15 million shsN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$86.54
-4.1%
$82.31
$23.30
$105.47
$5.62B2.111.33 million shs1.35 million shs
10 Best Stocks to Own - Summer 2026 Cover

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
-4.95%+6.87%-11.29%+0.40%+42.40%
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
+3.31%+3.66%+6.52%-0.19%+154.55%
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
0.00%0.00%0.00%+2.64%+162.82%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-4.13%-1.04%-13.32%+46.31%+140.46%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
2.78
Moderate Buy$44.8348.65% Upside
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
2.88
Moderate Buy$203.0028.13% Upside
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
2.21
Hold$41.332.06% Upside
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
2.70
Moderate Buy$90.304.34% Upside

Current Analyst Ratings Breakdown

Latest AVBP, CNTA, TWST, and BLTE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/22/2026
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
Reiterated RatingBuy
7/20/2026
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
UpgradeHoldStrong-Buy
7/17/2026
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
Reiterated RatingSell (D-)
7/16/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Set Price Target$110.00
7/14/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Boost Price TargetBuy$90.00 ➝ $120.00
7/6/2026
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
Reiterated RatingSell (D-)
7/6/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
DowngradeOutperformIn-Line$102.00
6/29/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Boost Price TargetBuy$60.00 ➝ $107.00
6/24/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Reiterated RatingSell (D-)
6/24/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Boost Price TargetOverweight$65.00 ➝ $95.00
6/15/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Boost Price TargetBuy$68.00 ➝ $89.00
(Data available from 7/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
N/AN/AN/AN/A$7.44 per shareN/A
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
N/AN/AN/AN/A$20.54 per shareN/A
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
N/AN/AN/AN/A$3.92 per shareN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$409.48M13.16N/AN/A$7.84 per share11.04
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
-$166.31M-$3.47N/AN/AN/AN/A-48.98%-45.44%8/14/2026 (Estimated)
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
-$77.61M-$2.53N/AN/AN/AN/A-13.14%-12.88%8/10/2026 (Estimated)
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
-$197.53M-$1.79N/AN/AN/AN/A-60.37%-44.17%8/11/2026 (Estimated)
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$77.67M-$1.33N/AN/AN/A-19.85%-26.73%-19.15%8/3/2026 (Estimated)

Latest AVBP, CNTA, TWST, and BLTE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2026Q2 2026
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
-$0.98N/AN/AN/AN/AN/A
8/11/2026Q2 2026
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
-$0.40N/AN/AN/AN/AN/A
8/10/2026Q2 2026
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
-$0.73N/AN/AN/AN/AN/A
8/3/2026Q3 2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$0.50N/AN/AN/A$114.55 millionN/A
5/15/2026Q1 2026
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
-$0.60-$0.34+$0.26-$0.68N/AN/A
5/11/2026Q1 2026
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
-$0.88-$0.96-$0.08-$0.96N/AN/A
5/5/2026Q1 2026
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
-$0.38-$0.52-$0.14-$0.52N/AN/A
5/4/2026Q2 2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$0.49-$0.71-$0.22-$0.71$107.64 million$110.72 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
N/AN/AN/AN/AN/A
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
N/AN/AN/AN/AN/A
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
N/AN/AN/AN/AN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
N/A
13.95
13.95
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
N/A
33.71
33.71
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
0.23
9.53
9.53
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
0.03
2.70
2.42

Institutional Ownership

CompanyInstitutional Ownership
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
9.48%
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
0.53%
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
82.01%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/A

Insider Ownership

CompanyInsider Ownership
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
8.58%
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
13.29%
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
4.09%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
3.08%
CompanyEmployeesShares OutstandingFree FloatOptionable
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
4046.58 million42.58 millionN/A
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
1040.08 million34.76 millionNot Optionable
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
200154.73 million148.40 millionOptionable
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
99062.27 million60.35 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ArriVent BioPharma stock logo

ArriVent BioPharma NASDAQ:AVBP

$30.16 -1.57 (-4.95%)
Closing price 07/27/2026 04:00 PM Eastern
Extended Trading
$29.71 -0.45 (-1.51%)
As of 04:28 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

Belite Bio stock logo

Belite Bio NASDAQ:BLTE

$158.43 +5.07 (+3.31%)
Closing price 07/27/2026 04:00 PM Eastern
Extended Trading
$158.17 -0.26 (-0.16%)
As of 04:11 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.

Centessa Pharmaceuticals stock logo

Centessa Pharmaceuticals NASDAQ:CNTA

$40.50 0.00 (0.00%)
As of 06/25/2026

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

Twist Bioscience stock logo

Twist Bioscience NASDAQ:TWST

$86.54 -3.73 (-4.13%)
Closing price 07/27/2026 04:00 PM Eastern
Extended Trading
$87.06 +0.52 (+0.60%)
As of 04:29 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.